Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalGynecologic Oncology
Volume116
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Epigenomics
Ovarian Neoplasms
decitabine
Pharmaceutical Preparations
DNA Methylation
Therapeutics
Drug Resistance
Appointments and Schedules
Animal Models
Biomarkers
Clinical Trials
Gene Expression
Cell Line
Ovarian epithelial cancer

Keywords

  • Chemosensitization
  • DNMTI
  • Epigenetics
  • HDAC inhibitor
  • Ovarian cancer
  • Platinum resistance

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. / Matei, Daniela; Nephew, Kenneth.

In: Gynecologic Oncology, Vol. 116, No. 2, 02.2010, p. 195-201.

Research output: Contribution to journalArticle

@article{fbca104bedca4062b015ded580286dda,
title = "Epigenetic therapies for chemoresensitization of epithelial ovarian cancer",
abstract = "Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.",
keywords = "Chemosensitization, DNMTI, Epigenetics, HDAC inhibitor, Ovarian cancer, Platinum resistance",
author = "Daniela Matei and Kenneth Nephew",
year = "2010",
month = "2",
doi = "10.1016/j.ygyno.2009.09.043",
language = "English",
volume = "116",
pages = "195--201",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

AU - Matei, Daniela

AU - Nephew, Kenneth

PY - 2010/2

Y1 - 2010/2

N2 - Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

AB - Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

KW - Chemosensitization

KW - DNMTI

KW - Epigenetics

KW - HDAC inhibitor

KW - Ovarian cancer

KW - Platinum resistance

UR - http://www.scopus.com/inward/record.url?scp=73949106115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949106115&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.09.043

DO - 10.1016/j.ygyno.2009.09.043

M3 - Article

VL - 116

SP - 195

EP - 201

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -